Italian Association of Nuclear Medicine, Molecular Imaging and Therapy (AIMN) practical guide for peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-Oxodotreotide in gastroenteropancreatic neuroendocrine tumors (GEP-NET)

被引：0

作者：

Laudicella, Riccardo ^{[1
]}

Albano, Domenico ^{[2
,3
]}

Bauckneht, Matteo ^{[4
,5
]}

Urso, Luca ^{[6
,7
]}

Bodei, Lisa ^{[8
]}

De Rimini, Maria Luisa ^{[9
]}

Grana, Chiara Maria ^{[10
]}

Baldari, Sergio ^{[1
]}

Versari, Annibale ^{[11
]}

Filice, Angelina ^{[11
]}

Bartolomei, Mirco ^{[7
]}

Maccauro, Marco ^{[12
]}

机构：

[1] Univ Messina, Dept Biomed & Dent Sci & Morpho Funct Imaging, Nucl Med, Messina, Italy

[2] ASST Spedali Civili Brescia, Nucl Med, Brescia, Italy

[3] Univ Brescia, Radiol Sci & Publ Hlth Dept, Brescia, Italy

[4] IRCCS Osped Policlin San Martino, Genoa, Italy

[5] Univ Genoa, Dept Hlth Sci DISSAL, Nucl Med, Genoa, Italy

[6] Univ Ferrara, Dept Translat Med, Ferrara, Italy

[7] Univ Hosp Ferrara, Oncohematol Dept, Nucl Med Unit, Ferrara, Italy

[8] Mem Sloan Kettering Canc Ctr, New York, NY USA

[9] AORN Osped Colli, Nucl Med Unit, Naples, Italy

[10] IRCCS, IEO European Inst Oncol, Milan, Italy

[11] Azienda USL IRCCS Reggio Emilia, Nucler Med Unit, Reggio Emilia, Italy

[12] Fdn IRCCS Ist Nazl Tumori, ENETS Ctr Excellence, Dept Nucl Med, Milan, Italy

来源：

CLINICAL AND TRANSLATIONAL IMAGING | 2025年 / 13卷 / 02期

关键词：

DOTA-peptide; Gastroenteropancreatic neuroendocrine tumor; Lutathera; Lutetium; Peptide receptor radionuclide therapy; RPT; ENETS CONSENSUS GUIDELINES; TYR(3) OCTREOTATE; FOLLOW-UP; LU-177-DOTATATE; STANDARDS; CARE; Y-90-DOTATOC; TOXICITY; EFFICACY;

D O I：

10.1007/s40336-025-00679-y

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Somatostatin receptors (SSTR) are overexpressed by most neuroendocrine tumors (NETs), and patients with SSTR-positive disease can be identified by DOTA-peptide PET. Phase II and III studies proved SSTR-targeted radiopharmaceutical therapy safe and effective in metastatic gastroenteropancreatic (GEP) NETs progressed after SST analogues. Additional data indicate that [177Lu]Lu-oxodotreotide peptide receptor radionuclide therapy (PRRT) also has high potential in earlier clinical situations. The purpose of this Italian procedural guideline is to assist the nuclear medicine personnel in the delivery of [177Lu]Lu-DOTA-peptide therapy, from patient selection to end-of-therapy follow-up, and to facilitate the management of possible side effects and their clinical management. The current document is based upon the current best practice and knowledge of experienced Centers and Nuclear Medicine Physicians in Italy.

引用

页码：105 / 120

页数：16

共 50 条

[1] Safety of [177Lu]Lu-oxodotreotide in gastroenteropancreatic neuroendocrine (GEP-NET) patients. Experience in our hospital.
Garcia Lama, L.
Franco Monterroso, C. G.
Hernandez Fructuoso, M. A.
Jimenez Pena, C.
Santos Montero, B.
Rey Sanchez, L.
Garcia Burillo, A.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S669 - S669
[2] The technologist role in 177Lu dosimetry for PRRT (Peptide Receptor Radionuclide Therapy)
Leoni, E.
Filice, A.
Palmieri, A.
Ghiraldini, G.
Fioroni, F.
Grassi, E.
Cola, S.
Versari, A.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S850 - S851
[3] Reduced efficacy of repeated peptide receptor radionuclide therapy (PRRT) in progressive gastroenteropancreatic neuroendocrine tumours (GEP-NET)?
Schnurr, J.
Reimold, M.
Dittmann, H.
Kupferschlaeger, J.
Bares, R.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S396 - S396
[4] Safety and efficacy of 177Lu DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) in progressive gastro-entero-pancreatic (GEP) Neuroendocrine Tumour (NET)
Alipour, R.
Karri, R. K.
Boehm, E.
Jewell, K.
Fahey, M.
Saghebi, J.
Cardin, A.
Neeson, L.
Buteau, J. P.
Kumar, A. Ravi
Akhurst, T.
Hofman, M.
Michael, M.
Hicks, R.
Kong, G.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S665 - S666
[5] COMPETE trial: Peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET
Pavel, M. E.
Rinke, A.
Baum, R. P.
ANNALS OF ONCOLOGY, 2018, 29
[6] Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors A Meta-analysis
Saravana-Bawan, Bianka
Bajwa, Amandeep
Paterson, John
McEwan, Alexander J. B.
McMullen, Todd P. W.
CLINICAL NUCLEAR MEDICINE, 2019, 44 (09) : 719 - 727
[7] Efficacy of the Chronic Lanreotide Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP/NET) after Peptide Receptor Radionuclide Therapy (PRRT)
Szalus, N.
Kaminski, G.
Podgajny, Z.
Dziuk, E.
NEUROENDOCRINOLOGY, 2009, 90 (01) : 137 - 137
[8] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE (177Lu) Is Effective and Safe in Patients with Pretreated Metastatic Neuroendocrine Tumors: Data from Spanish SEPTRALU Registry
Bello, P.
Jimenez-Fonseca, P.
Percovich, J. C.
Anido Herranz, U.
Gajate, P.
Castellon, M.
Estorch, M.
Gonzalez, E.
Field, C.
Garcia Alonso, P.
Carmona-Bayonas, A.
Mitjavila, M.
NEUROENDOCRINOLOGY, 2019, 108 : 198 - 198
[9] Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
Staanum, Peter Frohlich
Frellsen, Anders Floor
Olesen, Marie Louise
Iversen, Peter
Arveschoug, Anne Kirstine
EJNMMI PHYSICS, 2021, 8 (01)
[10] PFS and OS after Salvage Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors (GEP-NETs) - The Rotterdam Cohort
Van der Zwan, W.
Brabander, T.
Kam, B.
Teunissen, J.
Krenning, E.
Kwekkeboom, D.
de Herder, W.
NEUROENDOCRINOLOGY, 2018, 106 : 262 - 262

← 1 2 3 4 5 →